ASRT Quote, Financials, Valuation and Earnings

Harrow, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of 1.42%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Harrow, Inc.'s return on equity of -8.95%.

Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 239.56%. On the other hand Harrow, Inc. has an analysts' consensus of $70.63 which suggests that it could grow by 51.01%. Given that Assertio Holdings, Inc. has higher upside potential than Harrow, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Harrow, Inc..

Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Harrow, Inc. has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.168%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Harrow, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are smaller than Harrow, Inc. quarterly revenues of $71.6M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Harrow, Inc.'s net income of $1M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Harrow, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.56x versus 6.98x for Harrow, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of --. Assertio Holdings, Inc.'s return on equity of -25.86% beat Skye Bioscience, Inc.'s return on equity of -91.57%.

Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 239.56%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 581.82%. Given that Skye Bioscience, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.676, suggesting its more volatile than the S&P 500 by 167.642%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Assertio Holdings, Inc.'s net income of $11.4M is higher than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.56x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of 18.08%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 239.56%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 42.86%. Given that Assertio Holdings, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Theravance Biopharma, Inc..

Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.56x versus 11.74x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of 0.84%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2%.

Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 239.56%. On the other hand Xeris Biopharma Holdings, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 71.13%. Given that Assertio Holdings, Inc. has higher upside potential than Xeris Biopharma Holdings, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Xeris Biopharma Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Xeris Biopharma Holdings, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.307%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Xeris Biopharma Holdings, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are smaller than Xeris Biopharma Holdings, Inc. quarterly revenues of $74.4M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Xeris Biopharma Holdings, Inc.'s net income of $621K. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Xeris Biopharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.56x versus 4.03x for Xeris Biopharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.